Human Gene Set: ERWIN_COHEN_BLOOD_VACCINE_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_2DY_DN

GSEA and MSigDB Need Your Support

We are preparing a grant proposal to NCI's Information Technology for Cancer Research program for the continued funding of GSEA and MSigDB. Click here to learn how you can help. (show)


Standard name ERWIN_COHEN_BLOOD_VACCINE_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_2DY_DN
Systematic name M40951
Brief description Genes down-regulated in blood vaccinated vs control in adults (23-48) after exposure to Live attenuated vaccine TC-83 , time point 2D
Full description or abstract Venezuelan equine encephalitis virus (VEEV) is an important human and animal alphavirus pathogen transmitted by mosquitoes. The virus is endemic in Central and South America, but has also caused equine outbreaks in southwestern areas of the United States. In an effort to better understand the molecular mechanisms of the development of immunity to this important pathogen, we performed transcriptional analysis from whole, unfractionated human blood of patients who had been immunized with the live-attenuated vaccine strain of VEEV, TC-83. We compared changes in the transcriptome between naive individuals who were mock vaccinated with saline to responses of individuals who received TC-83. Significant transcriptional changes were noted at days 2, 7, and 14 following vaccination. The top canonical pathways revealed at early and intermediate time points (days 2 and 7) included the involvement of the classic interferon response, interferon-response factors, activation of pattern recognition receptors, and engagement of the inflammasome. By day 14, the top canonical pathways included oxidative phosphorylation, the protein ubiquitination pathway, natural killer cell signaling, and B-cell development. Biomarkers were identified that differentiate between vaccinees and control subjects, at early, intermediate, and late stages of the development of immunity as well as markers which were common to all 3 stages following vaccination but distinct from the sham-vaccinated control subjects. The study represents a novel examination of molecular processes that lead to the development of immunity against VEEV in humans and which may be of value as diagnostic targets, to enhance modern vaccine design, or molecular correlates of protection.
Collection C7: Immunologic Signature
      VAX: HIPC Vaccine Response
Source publication Pubmed 27870591   Authors: Erwin-Cohen RA,Porter AI,Pittman PR,Rossi CA,DaSilva L
Exact source Suppl mat, 2016HV0244R-s01.xlsx
Related gene sets (show 5 additional gene sets from the source publication)

(show 11 gene sets from the same authors)
External links https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287313/bin/khvi-13-01-1227900-s001.zip
Filtered by similarity ?
Organism Homo sapiens
Contributed by HIPC SIGNATURES (NIAID/HIPC SIGNATURES)
Source platform HUMAN_GENE_SYMBOL
Dataset references  
Download gene set format: grp | gmt | xml | json | TSV metadata
Compute overlaps ? (show collections to investigate for overlap with this gene set)
Compendia expression profiles ? GTEx compendium
Human tissue compendium (Novartis)
Global Cancer Map (Broad Institute)
NCI-60 cell lines (National Cancer Institute)
Advanced query Further investigate these 32 genes
Gene families ? Categorize these 32 genes by gene family
Show members (show 32 members mapped to 32 genes)
Version history 7.3: First Introduced.

See MSigDB license terms here. Please note that certain gene sets have special access terms.